The complex shape of respiratory syncytial virus is one hurdle limiting the development of treatments for an infection that leads to hospitalization or worse for hundreds of thousands of people in the ...
Respiratory syncytial virus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that ziresovir may have efficacy in the treatment ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications ...
In mice, common respiratory infections reactivated dormant cancer cells. Early evidence suggests the same may happen in humans, with big implications for long-term cancer risk. This colored ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback